Cetuximab, a chimeric IgG1 antibody against EGFR, and trastuzumab, a humanized IgG1 antibody against HER-2, are popular therapeutic antibodies that significantly improved the clinical outcome in EGFR- and HER-2-overexpressing human cancers, respectively [29]. Here, EGFR is linked to cancer.